

DAFTAR PUSTAKA

- Carvalho GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, et al. Correlation between serum PSA and cancer volume in prostate glands of different sizes. *Urology*. 2010;76(5); 1072-6
- Choi J, Ikeguchi EF, Lee SW, Choi HY, Te AE, et al. Is the higher prevalence of benign prostatic hyperplasia related to lower urinary tract symptoms in Korean men due to a high transition zone index? *Eur Urol* 2002; 42:7-11.
- Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms : Prevalence and Incident Rates. *Urologic Clinics of North America*. *Urol Clin N Am*. 2016; 43(3): 289–297
- Epstein JI. Pathology of Prostatic Neoplasia. In Campbell M, Wein A, Kavoussi L, Walsh P. *Campbell-Walsh urology*. Philadelphia: Elsevier; 2016; p2593-600
- Epstein, J.I., Amin, M.B., Beltran, H., Lotan, T.L., Mosquera, J.M., Reuter, V.E., Robinson, B.D., Troncoso, P. and Rubin, M.A., 2014. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. *The American journal of surgical pathology*, 38(6), p.756.
- Epstein, J.I., Egevad, L., Amin, M.B., Delahunt, B., Srigley, J.R., Humphrey, P.A. and Grading Committee, 2016. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. *The American journal of surgical pathology*, 40(2), pp.244-252.
- Hulley SB, Cummings SR, Browner WS, Grady D, Newman TB. *Designing clinical research : an epidemiologic approach*. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. p 79.
- Köpke TE. Negative predictive value of systematic ultrasound-guided prostate biopsy: which tumours do we miss? - PubMed - NCBI [Internet]. *Ncbi.nlm.nih.gov*. 2016 [cited 4 October 2016]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/20592386>
- Kuriyama, M., Ueno, K., Uno, H., Kawada, Y., Akimoto, S., Noda, M., Nasu, Y., Tsushima, T., Ohmori, H., Sakai, H. and Saito, Y., 1998. Clinical Evaluation of Serum Prostate-Specific Antigen-Alpha1-Antichymotrypsin Complex

Values in Diagnosis of Prostate Cancer: A Cooperative Study. *International journal of urology*, 5(1), pp.48-54.

Lepor H, Shapiro E, Wang B, Liang YC. Comparison of the cellular composition of benign prostatic hyperplasia in Chinese and Caucasian-American men. *Urology*. 1996; 47: 38-42.

Loeb S, Eastham JA. Diagnosis and Staging of Prostate Cancer. In Campbell M, Wein A, Kavoussi L, Walsh P. *Campbell-Walsh urology*. Philadelphia: Elsevier; 2016; p2601-9

Lojanapiwat B, Anutrakulchai W, Chongruksut W, Udomphot C. Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. *Prostate International*. 2014;2(3):133-9.

Lotan, T.L. and Epstein, J.I., 2010. Clinical implications of changing definitions within the Gleason grading system. *Nature Reviews Urology*, 7(3), p.136.

Mochtar CA, Umbas R, Soebadi DM, Rasyid N, Noegroho BS, Poernomo BB, et al. *Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak*. Ikatan Ahli Urologi Indonesia. 2015. Diunduh 4 November 2016.

Mochtar CA, Umbas R, Soebadi DM, Rasyid N, Noegroho BS, Poernomo BB, et al. *Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak*. Ikatan Ahli Urologi Indonesia. 2015. Diunduh 4 November 2016. Tersedia dari: [http://www.iaui.or.id/ast/file/Guideline_BPH_\(2015\).pdf](http://www.iaui.or.id/ast/file/Guideline_BPH_(2015).pdf)

Morgan TM, Palapattu GS, Partin AW, Wei JT. Prostate Cancer Tumor Markers. In Campbell M, Wein A, Kavoussi L, Walsh P. *Campbell-Walsh urology*. Philadelphia: Elsevier; 2016; p2565-77

Netto, G.J. and Epstein, J.I., 2010. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. *Pathology*, 42(4), pp.384-394.

Powell, I.J., Bock, C.H., Ruterbusch, J.J. and Sakr, W., 2010. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. *The Journal of urology*, 183(5), pp.1792-1797.

Presti, J.C. Neoplasms of the Prostate Cancer. In: Tanagho EA, McAninch JW. *Smith's General Urology*, Sixteenth edition. USA: The McGraw-Hill Companies, 2010. p367-84.

- Putra IBOW, et al. Relationship of age, prostate-specific antigen, and prostat volume in Indonesian men with benign prostatic hyperplasia. *Prostate Int.* 2016. Available from: <http://dx.doi.org/10.1016/j.pnil.2016.03.002>
- Rahardjo D, Birowo P, Pakasi L. Correlation between prostate volume, prostate specific antigen level, prostate specific antigen density and age in the benign prostate hyperplasia patients. *Med J Indones.*1999;260.
- Roehrborn, CG. et al. 2016. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History in Campbell – Walsh Urology. 11th edition. Philadelphia: Elsevier Saunders
- Sciarra, A. et al., 2008. Prostat Growth and Inflammation. *Journal of Steroid Biochemistry & Molecular Biology*,108, pp.254-260.
- Silverio, FD. et al. 2002. Distribution of Inflammation, Pre-Malignant Lesions, Incidental Carcinoma in Histologically Confirmed Benign Prostatic Hyperplasia: A Retrospective Analysis. *European Urology*, 43, pp.164-175.
- Tjahjodjati, Soebadi, DM., et al, 2017. Panduan Pelaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostat Hyperplasia). Ikatan Ahli Urologi Indonesia.
- Tomlins, S.A., Bjartell, A., Chinnaiyan, A.M., Jenster, G., Nam, R.K., Rubin, M.A. and Schalken, J.A., 2009. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. *European urology*, 56(2), pp.275-286.
- Udeh E,Dakum N, Amu O, Ramyl V. Correlation between serum prostate specific antigen and prostate volume in Nigerian men with biopsy proven benign prostatic hyperplasia : prospective study). *Int J Urol.* 2009;7(2)
- Lim KB. Epidemiology of benign prostatic hyperplasia. *Asian Journal of Urology.* 2017;4(3):148
- Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. *Indian J Urol.* 2014;30(2):170-171
- Deori R, Das B, Rahman MA. A Study of Relation ship of Prostate Volume, Prostate Specific Antigen adn age in Benign Prostatic Hyperplasia. *IJCMR.* 2017;4(7):1583

- Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions. *International Journal of Endocrinology*. 2014;X(X):1-2
- Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. *International Journal of Andrology* 2010;33:479
- Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, *et al.* Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. *European Urology*. 2014;66:619
- Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. *Experimental Gerontology*. 2005;40:124-5
- Verhamme KMC, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MCJM. Incidence and Prevalence of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Primary Care-The Triumph Project. *European Urology*. 2002;42:323
- Almarkhan MH, Sawma AI, Alruwaili FS, Alsaqabi QA, Alonazi MA, *et al.* Prevalence of Benign Prostatic Hyperplasia (BPH) in Saudi Patients above 40 Years Old. *The Egyptian Journal of Hospital Medicine*. 2018;70(7):1137
- Nickel JC. Benign Prostatic Hyperplasia: Does Prostate Size Matter?. *Rev Urol*. 2003;5:12-13
- Zhang S, Qian H, Zhao Y, Sun K, Wang H, Liang G. Relationship between age and prostate size. *Asian J Androl*. 2013;15(1):116
- Gandaglia G, Briganti A, Gontero P, Modaini N, Novara G, *et al.* The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). *BJU International*. 2013;112:434
- Robert G, Descazeaud, Nicolaiew N, Terry S, Sirab N, Vacherot F, *et al.* Inflammation in benign prostatic hyperplasia: a 282 patients immunohistochemical analysis. *Prostate*. 2009;69(16):1774

- Balk SP, Ko Y, Bublely GJ. Biology of Prostate-Specific Antigen. *Journal of Clinical Oncology*. 2003;21(2):383
- Malati T, Kumari GR, Murthy PVLN, Reddy CR, Prakash BS. Prostate Specific Antigen in Patients of Benign Prostate Hypertrophy and Carcinoma Prostate. *Indian Journal of Clinical Biochemistry*. 2006;12(1):34
- Krisna DM, Maulana A, Kresnodi E. correlation between Prostate-Specific-Antigen (PSA) Level and Prostate Volume in Benign Prostatic Hyperplasia at Bhayangkara Hospital Mataram. *Journal Of Medicine and Health*. 2017;1(6):525
- Mittal RD. Reference range of serum prostate-specific antigen levels in Indian men. *Indian J Med Res*. 2014;140(4):480
- Ingle SP, Ramona I, Sukesh. The efficiency of the Serum Prostate Specific Antigen Levels in Diagnosing Prostatic Enlargements. *J Clin Diagn Res*. 2013;7(1):82
- Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. *J Urol*. 1995;154(1):407
- Cakir SS, Polat EC, Ozcan L, Besiroglu H, Otunctemur A, Ozbek E. The effect of prostatic inflammation on clinical outcomes in patients with benign prostate hyperplasia. *Prostate Int*. 2018;6(2):71
- Meert T, Baten E, van Renterghem K. Clinical Importance of Histopathological Inflammation in Patients with Lower Urinary Tract symptoms Due to Benign Prostatic Hyperplasia: Aprospective Study of 222 patients. *Curr Urol*. 2016;10:1
- J. Irani, P. Levillan, J.M. Gouion, D. Bon, B. Dore, J. Aubert
Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value, *J. Urol*. 157 (4) (1997) 1301-1303.